Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 3/20 | 0.71 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.70 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.70 |
| ▸ | CDK2 | P24941 | 3/20 | 0.63 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501045 | 0.83 | TGFBR1 (1.00) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL12501089 | 0.80 | TGFBR1 (0.63) | IKBKETGFBR1PDPK1DYRK1ACDK2 | |
| SCHEMBL3379371 | 0.78 | IKBKE (0.54) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL3386469 | 0.77 | IKBKE (0.52) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL14876853 | 0.76 | DYRK1A (0.59) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL12501062 | 0.75 | IKBKE (0.64) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL3378612 | 0.74 | TGFBR1 (0.52) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL16572576 | 0.73 | TGFBR1 (0.67) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL17179566 | 0.73 | DYRK1A (1.00) | IKBKETGFBR1PDPK1DYRK1ANFATC1 | |
| SCHEMBL3382263 | 0.73 | IKBKE (0.50) | IKBKETGFBR1PDPK1DYRK1ANFATC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | IKBKE 52/4885TGFBR1 1/4885PDPK1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.